Winfried Wels

Professor for Tumor Biology and Biology of Infectious Diseases

Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Germany



Dr. Winfried Wels has a strong interest in translational cancer research with over twenty five years of experience in cancer immunotherapy. In recent years, he and his group pioneered approaches to enhance the therapeutic utility of natural killer (NK) cells through expression of chimeric antigen receptors (CARs) targeting various tumor-associated antigens. This includes the development of CAR-engineered, continuously expanding human NK-92 cells as novel off-the-shelf cellular therapeutics. ErbB2 (HER2)-specific CAR NK-92 cells are currently being developed for clinical application in a phase I clinical trial in patients with recurrent ErbB2-positive glioblastoma. Dr. Wels holds a Diploma in Biology and a doctoral degree in Microbiology, which he received both from the University of W├╝rzburg, Germany. He is currently Deputy Director and a member of the Executive Board of Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy in Frankfurt, Germany, an independent, publicly funded academic research institute associated with the University of Frankfurt. Dr. Wels is also a full Professor for Tumor Biology and Biology of Infectious Diseases at the Medical Faculty of the University of Frankfurt, a member of the LOEWE Center for Cell and Gene Therapy in Frankfurt, a speaker of the research topic Advanced Cellular Therapeutics within the Cancer Immunotherapy program of the German Cancer Consortium (DKTK), and a coordinator of the Cancer Immunotherapy program of the DKTK partner site Frankfurt/Mainz.